Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | S100A4 | P26447 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458459 | 0.84 | CHRNB2 (0.39) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL5621945 | 0.84 | CHRNB2 (0.39) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL5622654 | 0.80 | CHRNB2 (0.40) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL5621125 | 0.80 | CHRNB2 (0.40) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL14474348 | 0.79 | CHRNB2 (0.39) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL11444096 | 0.76 | TDP1 (0.42) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL5916971 | 0.76 | GPR35 (0.46) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL2246781 | 0.75 | GPR35 (0.42) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL8611307 | 0.74 | CHRNB2 (0.39) | ACHECHRNB2CHRNA4TDP1GPR35 | |
| SCHEMBL12355698 | 0.73 | CHRNB2 (0.40) | ACHECHRNB2CHRNA4TDP1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN KETTERING INST CANCER (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN KETTERING INST CANCER (US) | 2015-10-01 | — | — | US | disclosed |
| US-9056857-B2 | Methods for treating or preventing cancer and neurodegenerative diseases | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056857-B2 | Methods for treating or preventing cancer and neurodegenerative diseases | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2010075255-A2 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | ACHE 3868/4885CHRNB2 2871/4885CHRNA4 2174/4885 |
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN2 | ACHE 38/4885CHRNB2 163/4885CHRNA4 339/4885 |
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN2 | ACHE 38/4885CHRNB2 163/4885CHRNA4 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.